All Resources

Opioid agonist therapy. Gap Coverage Program : information for health care providers

Description

Opioid agonist therapy (OAT), which entails the provision of medications like oral buprenorphine/naloxone, methadone or injectable extended-release buprenorphine, is an evidence-based treatment... More ≫

Description

Opioid agonist therapy (OAT), which entails the provision of medications like oral buprenorphine/naloxone, methadone or injectable extended-release buprenorphine, is an evidence-based treatment option for opioid use disorder. This fact sheet provides information for health care providers about the OAT Gap Coverage Program, which is designed to provide immediate, no-cost access to OAT drugs for patients who do not have supplementary health benefit coverage.

Tags

Opioid agonist therapy. Gap Coverage Program : information for patients

Description

Opioid agonist therapy (OAT), which entails the provision of medications like oral buprenorphine/naloxone, methadone or injectable extended-release buprenorphine, is an evidence-based treatment... More ≫

Description

Opioid agonist therapy (OAT), which entails the provision of medications like oral buprenorphine/naloxone, methadone or injectable extended-release buprenorphine, is an evidence-based treatment option for opioid use disorder. This fact sheet provides information for patients about Gap Coverage Program, which is designed to provide immediate, no-cost access to OAT drugs for patients who do not have supplementary health benefit coverage.

Tags